| Prev Close | 45.96 |
| Open | 45.96 |
| Day Low/High | 45.95 / 45.99 |
| 52 Wk Low/High | 22.11 / 46.01 |
| Volume | 9.49M |
| Avg Volume | 4.75M |
| Exchange | |
| Shares Outstanding | 108.58M |
| Market Cap | 4.99B |
| EPS | -0.08 |
| Div & Yield | N.A. (N.A) |
Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.
Cramer says take the money and run on NPS Pharmaceuticals, stay away from VMware and he missed the boat on OvaScience.
Many of the stocks hit hard Wednesday will rise again soon enough, Cramer says.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of NPS...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of NPS Pharmaceuticals Inc.
Levi & Korsinsky is investigating the Board of Directors of NPS Pharmaceuticals Inc.
Cramer remains a big fan of Alcoa and thinks Acorda Therapeutics is exactly what investors should be looking for in a growth stock.
The restaurants and the biotechs tried their best to save us but it just wasn't enough, Cramer says.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NPS Pharmaceuticals, Inc.
Kirby McInerney LLP is investigating potential claims against NPS Pharmaceuticals, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of NPS...
Here's what analysts were saying about Shire's takeover of NPS Pharmaceuticals.
Oil continues to pressure stock markets on Monday following a price warning from Goldman Sachs analysts.
TheStreet's Jim Cramer explains why he likes Shire's (SHPG) deal to buy NPS Pharmaceuticals (NPSP) for $5.2 billion in an all-cash transaction.
TheStreet highlights 3 stocks pushing the health care sector higher today.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of NPS...
Stocks fall as investors flee energy stocks.
Levi & Korsinsky is investigating the Board of Directors of NPS Pharmaceuticals Inc.
NPS Pharmaceuticals (NPSP) shares are climbing after the company agreed to be purchased by Shire plc for $5.2 billion.
The Rosen Law Firm announces that it is investigating the Board of Directors of NPS Pharmaceuticals, Inc.
The Dublin company bounces back three months after the collapse of its own $49 billion takeover by AbbVie.
Stock futures rise slightly Monday morning following Friday's volatile session.
Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a pre-market mover with heavy volume candidate
U.S. stock futures rise; Shire agrees to buy NPS Pharmaceuticals for $5.2 billion; GM to roll out a $30,000 electric vehicle; Alcoa kicks off fourth-quarter earnings season.
European markets rebound on Monday, as news of a series of pharma industry deals seemed to indicate a renewal of confidence after last week's falls.
